31^st International Workshop on HIV Drug Resistance and Treatment Strategies
POSTER ABSTRACTS

View the PDF posters, and corresponding short video presentations below.  

Abstract Number (as per the eBook);  Abstract Title;  Initial;  Surname

• 4 Dolutegravir Resistance among Virally Non-Suppressed Adults and Children Remains Low in South Africa | C van der Walt
• 14 Dolutegravir Resistance Detected More Frequently When Co-administered with Zidovudine or Abacavir Compared to Tenofovir | C Boyce
  • 14 Video link
• 17 Evaluation of Dried Blood Specimens for HIV-1 Drug Resistance Testing Using a Commercial  HIV Drug Resistance Assay | O Okafor
  • 17 Video link
• 18 Trends of Major Dolutegravir Mutations in HIV-1 Virologic Failure in Kampala Uganda, 2021-2023 | J Owori
  • 18 Video link
• 19 The Clinical Management of Clients with HIV Genotypic Resistance Testing in Five South African Districts | L Gilbert
  • 19 Video link
• 20 Profile of Antiretroviral Resistance in Children Born to HIV-Positive Mothers on Dolutegravir in Togo from 2021 to 2023 | K Tegueni
  • 20 Video link
• 21 Low Acquired Dolutegravir Resistance Among PLHIV with Low Level Viremia in Uganda: A National Laboratory Survey Using Remnant Samples during November 2022 - June 2023 | G  Namayanja
  • 21 Video link
• 22 Pre Treatment HIV Drug Resistance Among Individuals Initating ART In Greater Gaborone, Botswana | N Moraka
  • 22 Video link
• 23 Analysis of Dolutegravir Resistance Patterns from a Private Laboratory, South Africa. | R Mafuyeka
  • 23 Video link
• 24 KwaZulu-Natal Paediatric Third-line Antiretroviral Therapy Committee Post-Implementation Experiences and HIV Drug Resistance Patterns | A Khan
  • 24 Video link
• 25 Adolescents with confirmed virological failure stand at risk of acquiring resistance to dolutegravir and need novel treatment options: Findings during the early stage of TLD transition in the CIPHER-ADOLA study | Y Bouba
  • 25 Video link
• 27 The Patterns of HIV Drug Resistance in Newly Diagnosed Infants in KwaZulu-Natal Province, South Africa. | T Mosito
  • 27 Video link
• 28 HIV Viral Load Suppression Amongst the Incarcerated Populations in Cameroon | A Fualefac
  • 28 Video link
• 29 Pre-treatment Doravirine Drug Resistance in an Antiretroviral (ART) Naïve South African Cohort | J Woods
  • 29 Video link
• 30 HIV Drug Resistance Profiles Amongst Participants Who Were Virally Non-suppressed in the Sixth South African National HIV Prevalence, Incidence and Behavior Survey (SABSSM VI), 2022 | S Moyo
  • 30 Video link
• 31 Outcomes After Switch to Protease Inhibitor-based Antiretroviral Therapy Among People with Acquired Dolutegravir Resistance in Lesotho | B Lukau
  • 31 Video link
• 32 Optimisation of an In-house Multiplex PCR for Antiretroviral Drug Resistance Testing | K van Eck
  • 32 Video link
• 33 Acquired HIV Drug Resistance to Dolutegravir among Persons Living with HIV in Uganda: Analysis of Uganda National Viral Load Program Remnant Specimens Surveillance data, 2023 | C Watera
  • 33 Video link
• 34 Frequency of Mutations in the 3′ Polypurine Tract (3'-PPT) of nef in People with Viraemia on Dolutegravir-Based ART Across HIV-1 Subtypes in Africa | J Giandhari
  • 34 Video link
• 35 Low Frequency Integrase Drug Resistance Mutations in People With Virological Failure on Dolutegravir-based Antiretroviral Therapy | S Naidoo
  • 35 Video link
• 36 Emergence of Dolutegravir resistance in integrase strand transfer inhibitor-naïve  patients in KwaZulu-Natal, South Africa | M Pillay
  • 36 Video link
• 37 Pretreatment HIV Drug Resistance in Adults in Ukraine in 2023 | M Liulchuk
  • 37 Video link
• 38 Possible Alternative Mechanism of Resistance to Dolutegravir in ARTIST after 2 Years on Second-Line Antiretroviral Therapy | K Delaney
  • 38 Video link
• 39 Rapid Drug Resistance Development During Initial Dolutegravir Treatment of an Infant with HIV | T von Mollendorff
  • 39 Video link
• 40 Treatment Outcomes in Patients who Switched to Dolutegravir Following Failure of a Protease Inhibitor-based ART regimen | M Kakubu
  • 40 Video link
• 41 HIV Non-Suppression and Antiretroviral Drug Resistance in Angola Based Results from a Nationally Representative Cross-Sectional Survey | B Pocongo
  • 41 Video link
• 42 Most instances of persistent low-level HIV viremia during ART are not attributable to either low antiretroviral drug levels or emerging drug resistance | A Cabral da Silva 
  • 42 Video link
• 43 Persistent (> 6 year) Detectable Plasma Viral Loads Caused by DNA Contamination from a Massively Clonally-Expanded, Genetically-Defective, Drug-Susceptible Provirus | E Barad
  • 43 Video link
• 45 HIV Superinfections and Dolutegravir Resistance in South Africa: a Modelling Study | G  Wick
  • 45 Video link
• 46 Trends in Pretreatment Drug-Resistance in Japan, 2020–2023: Increase in M184V Prevalence Among Treatment-Naive Individuals and Association with PrEP Use | T Kikuchi
  • 46 Video link
• 47 Mutational Pathways of Emergent Dolutegravir Resistance in the DTG RESIST Study | R Schill
  • 47 Video link
• 48 Selection of mutations in the 3’ polypurine tract of HIV-1 under selective drug pressure with integrase inhibitors | J van Osch
  • 48 Video link
• 49 Novel Associations between Integrase Mutations and Genotypic DTG Resistance in the DTG RESIST Study | N Han
  • 49 Video link
• 50 Low Prevalence of Lenacapavir Resistance Among Treatment-Experienced People Living with HIV in South Africa | L Gaelejwe
  • 50 Video link
• 51 Accurate Detection of Dolutegravir and Protease Inhibitor Resistance Mutations Using the Pan Degenerate Amplification and Adaptation (PANDAA TM) Assay | B Buma
  • 51 Video link
• 52 Characteristics and Outcome of Children and Adolescents Referred to the Third-Line Antiretroviral Therapy Programme in the Western Cape province, South Africa: an 8-year Review | N O'Connell  
  • 52 Video link
• 53 Estimating the Genetic Barrier for Resistance to Integrase Inhibitors for the Most Frequently Circulating HIV-1 Subtypes | J van Kampen
• 54 HIV drug resistance among adults with HIV and TB receiving bictegravir- or dolutegravir-based ART, during rifampicin-based TB treatment in South Africa: INSIGHT trial | B Chimukangara
  • 54 Video link
• 55 Prevalence of Epistatic HIV env and gag Mutations in People with HIV with Persistent Low-level Viremia Using a Dolutegravir-containing Regimen in São Paulo, Brazil | R Diaz - Video link
• 56 Optimization and Verification of IonTorrent Next-Generation Sequencing Workflow for HIV Drug Resistance Genotypic Testing. | C Seema
• 57 Virological re-suppression in the presence of major dolutegravir resistance mutations: a case series. | L du Toit
  • 57 Video link
• 58 Quantitative Detection of Low Levels of Drug Resistance to Nucleoside Reverse Transcriptase Inhibitors by RT-qPCR | D Mims
  • 58 Video link
• 59 An Enzymatic Assay for Rapid Measurement of Tenofovir Diphosphate with Lateral Flow Readout | M Singh
  • 59 Video link
• 60 HIV Drug Resistance in Indonesian Persons with HIV and Virologic Failure in the INA-PROACTIVE Study: Distinct Resistance Profiles in Adults and Children | W Wulan
  • 60 Video link
• 63 Pan-resistant HIV-1 in adults and adolescents with viraemia on dolutegravir-based ART in Africa | C Chimbetete
  • 63 Video link
• 64 Pre-treatment HIV Drug Resistance Among Treatment-Naïve Infants and Children Newly Diagnosed with HIV in Papua New Guinea: Results from Clinic-Based Surveillance | A Kelly-Hanku
  • 64 Video link

Disclaimer: Abstract presentation videos are provided as unlisted YouTube links and are intended solely for the conference use - restrictions apply.